



Results First Half Year 2008

- Half Year EBITDA at record level
- Focus on product innovation fuels gross margin growth
- Geographic spread evolves well-balanced towards emerging markets and most profitable regions
- Higher EPS thanks to higher profit and lower number of shares

Nazareth (Belgium), 28 August 2008 (5:45 PM CET) – Today, Omega Pharma is publishing the interim financial statement for the period ending June 30, 2008 in a separate document that can be found at www.omega-pharma.be. This press release includes a selection of key figures and related comments.

Key figures related to the OTC activities

Consolidated results in thousand euro	First Half Year		
	2008	2007	Evolution
Net turnover	423 652	422 392	+0%
Operating cash flow (EBITDA) ⁽¹⁾	75 145	74 137	+1%
<i>As a % of the net turnover</i>	17.7%	17.6%	
Depreciations & amortization (DA)	-9 296	-7 735	
Non-recurring items	-2 952	-2 814	
Operating result (EBIT)	62 897	63 588	-1%
Financial result	-15 420	-16 412	
Earnings Before Taxes (EBT)	47 478	47 176	+1%
Income tax	-8 207	-8 187	
Net profit for the period	39 271	38 989	+1%
Recurring net profit for the period	41 713	41 315	+1%
Data per share			
Average number of shares ⁽²⁾	24 059 515	25 843 264	
Net profit / share (EPS)	1.63	1.51	+8%
Recurring net profit / share	1.73	1.60	+8%

(1) Operating result before non-recurring items, increased with depreciations and amortization.

(2) Calculated on the basis of the weighted average number of shares, after deduction of treasury shares

The figures in the chart above only refer to the OTC activities of Omega Pharma. When taking the 24% participation of Arseus into account, the recurring net profit amounts to 44.1 million euro and the recurring net profit per share to 1.83 euro.

Profitability at all-time high

As a result of a weaker first quarter and the positive swing in the second quarter 2008, the consolidated turnover remained stable versus the strong first half of 2007.

The gross margin grew from 57.2% last year to 59.1% thus underscoring the high added value of Omega Pharma OTC products. The increase in the gross margin is primarily the result of the growing contribution of product innovations; own Star and Key Brands, combined with economies of scale.

The recurring operating cash flow grew 1% at a stable turnover. The positive change in the evolution of the turnover during the second quarter 2008 was supported by enhanced activities in the field of product development, marketing and sales. The improved gross margin clearly exceeded the increase in corresponding costs.

Consolidated results in EUR million (and %)	Turnover First Half Year			EBITDA ⁽¹⁾ First Half Year			% 1H08 turnover
	2008	2007	Evolution	2008	2007	Evolution	
Belgium	102.9	113.9	-9.7%	15.5	15.1	+2.6%	15.1%
France	100.3	98.4	+1.9%	12.3	10.8	13.9%	12.3%
Northern Europe	55.6	54.1	+2.8%	15.0	14.3	+4.9%	27.0%
Southern Europe	88.6	84.1	+5.4%	15.2	17.4	-12.6%	17.2%
Rest Of World	76.2	71.9	+6.0%	22.1	21.1	+4.7%	29.0%
Omega Pharma (OTC)	423.6	422.4	+0.3%	80.1	78.7	+1.8%	18.9%
Total Omega Pharma ⁽²⁾	423.6	422.4	+0.3%	75.1	74.1	+1.3%	17.7%

⁽¹⁾ Operating result before non-recurring items, increased with depreciations and amortization.

⁽²⁾ Including non-allocated items

Thanks to a constantly improving geographic spread the temporarily lower performance in Southern Europe was compensated for by the traditionally high profitability in Northern Europe and the Emerging Markets (included in the segment 'Rest Of World'). In addition, the organizations in Belgium and France also achieved a remarkable improvement in profitability as a result of tight cost controls.

The non-recurring items are mainly related to restructurings and corresponding dismissal charges, as noted in the first quarter 2008 Trading Update.

The financial result was 6% more favorable and was impacted by the proceeds from the Arseus IPO, higher interest rates and the share buy-back program.

The recurring net profit is 1% above the level of the comparable period in the previous year. Thanks to the cancellation of treasury shares and the continuation of the share buy-back program, the corresponding amount per share is 1.73 euro - i.e. 8% higher than on June 30, 2007.

Prognosis ⁽¹⁾

Based on the developments in the first six months and the numerous initiatives scheduled for the second half of 2008 in a growing number of countries, Omega Pharma confirms its prognosis to achieve a growth in turnover of 3% to 7% for 2008.

At its Investors Day on September 11, 2008 the Group will present its current and future position in the OTC sector.

Omega Pharma, een pure OTC play

Since its creation in 1987, Omega Pharma has grown into a multinational group with approximately 2,000 staff and with operations in over 30 countries. Omega Pharma is one of the few global companies dealing solely in OTC products and is poised to enter the worldwide Top Ten ranking in the market for over-the-counter medicines and personal care products.

(1) **Disclaimer:** This press release contains forward-looking information which is based on current internal estimates and expectations as well as market expectations. Forward-looking statements contain inherent risks and apply exclusively on the date they are made. The actual results may differ substantially from those included in the forward-looking statements.

Important additional information:

- The interim financial report for the period ending June 30, 2008 is simultaneously published with this press release on www.omega-pharma.be.
- The financial statements in this interim financial report have been the subject of a limited external review. The report of the external auditor is also included in that report.
- The responsible managers of Omega Pharma NV state that the interim financial report provides a fair overview of the situation. Their formal statement is included in the interim financial report.
- This press release has been prepared in Dutch and has been translated into English. The Company has made all reasonable efforts to assure consistency between both versions. In case of doubt, the Dutch version prevails.

For more information, please contact:

Chris.Vanraemdonck@omega-pharma.be

Tel. 0032/9/381.03.31 - Mobile 0032/499/58.55.31

Financial calendar

Thursday September 11, 2008	Investors Day
Thursday October 16, 2008 (5:45 PM CET)	Trading Update (sales figures) 3 rd quarter 2008
Thursday 22 januari 2009 (5:45 PM CET)	Trading Update (sales figures) 4 th quarter 2008 and Full Year 2008